Nur Nicholson

CIK 1827317 · Chief Technical Officer · last filed 2026-05-14

Nur Nicholson is a Chief Technical Officer who has filed 22 SEC Form 4 insider transactions across 1 company since 2021. The most recent filing, for APLS, was dated May 14, 2026. Across all open-market trades the lifetime net is −$2.4M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

22

Lifetime Open-Market Net

-$2.45M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Apellis Pharmaceuticals, Inc. (APLS) Delisted Chief Technical Officer 24,284 $41.03 $996.4K -$2.45M 22 2026-05-14

Recent Filings

22 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2026-05-14 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed −204,277 $0 EDGAR
2026-01-30 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) +45,220 $0 EDGAR
2026-01-23 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −7,725 -$168.1K EDGAR
2026-01-21 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −2,203 -$43.6K EDGAR
2026-01-15 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −2,618 -$58.1K EDGAR
2025-06-11 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) $0 EDGAR
2025-01-30 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −825 -$24.4K EDGAR
2025-01-23 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −3,948 -$120.1K EDGAR
2025-01-21 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed +34,281 -$64.3K EDGAR
2025-01-14 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −2,632 -$75.5K EDGAR
Showing 110 of 22
Page 1 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.